Paclitaxel and pazopanib in ovarian cancer

Richardson and colleagues published an interesting article investigating the efficacy and safety of a novel combination of paclitaxel and pazopanib vs paclitaxel and placebo in patients with persistent or recurrent ovarian cancer. Interest in angiogenesis in ovarian cancer has increased in recent years after the positive results achieved with bevacizumab therapy. The study by Richardson et al was designed according to the MITO 11 phase 2 trial by Pignata et al and the phase 1 trial by Tan et al. Despite the fact that the programmed end points were not reached and the study had negative results, in our opinion the article deserves some comments.